


New therapies for melanoma: understanding cancer biology translates into new therapies

Keith T. Flaherty, M.D.


Massachusetts General Hospital
Cancer Center

Unraveling the cancer genome





BRAF mutations in human cancer


June, 2002: BRAF mutations
in 7% of cancer




PET Scans at Baseline and Day 15 on vemurafenib




Maximal tumor shrinkage by individual patient



Maximal tumor shrinkage by individual patient



Overall survival (1st interim analysis)




No. of patients in follow up

Dacarbazine	336	283	192	137	98	64	39	20	9	1	1
Vemurafenib	336	320	266	210	162	111	80	35	14	6	1

Understanding the consequences of cancer molecular biology


Immunologic interface: the breaks



Pre-treatment




4 doses
ipilimumab




Week 12 (10/06)



No drug



12/06




Courtesy
J. Wolchok
(MSK)

5/07



Ipilimumab phase III trial



Hodi FS et al. N Engl J Med. 2010 Aug 19;363(8):711-23.

Investment in cancer research is
paying off for patients now